Vlad Coric - 06 Jan 2022 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role
Chief Executive Officer, Director
Signature
/s/ George Clark, Attorney-in-Fact
Issuer symbol
BHVN
Transactions as of
06 Jan 2022
Net transactions value
-$1,322,260
Form type
4
Filing time
07 Jan 2022, 20:16:39 UTC
Previous filing
11 Feb 2022
Next filing
28 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $0 +12,500 +49% $0.000000 38,072 06 Jan 2022 Direct
transaction BHVN Common Shares Tax liability $725,076 -5,854 -15% $123.86* 32,218 06 Jan 2022 Direct F1
transaction BHVN Common Shares Options Exercise $0 +10,000 +31% $0.000000 42,218 07 Jan 2022 Direct
transaction BHVN Common Shares Tax liability $597,184 -4,634 -11% $128.87* 37,584 07 Jan 2022 Direct F1, F2
holding BHVN Common Shares 19,130 06 Jan 2022 By 401(K) Plan
holding BHVN Common Shares 100,000 06 Jan 2022 By The Vladimir Coric GRAT - 2019
holding BHVN Common Shares 331,000 06 Jan 2022 By The Vladimir Coric Marital Trust F3
holding BHVN Common Shares 470,000 06 Jan 2022 By: The Vladimir Coric Family Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Restricted Share Unit Award Options Exercise $0 -12,500 -33% $0.000000 25,000 06 Jan 2022 Common Shares 12,500 Direct F3, F4, F5
transaction BHVN Stock Option (Right to Buy) Award $0 +70,000 $0.000000 70,000 07 Jan 2022 Common Shares 70,000 $128.87 Direct F6
transaction BHVN Restricted Share Unit Award Award $0 +40,000 $0.000000 40,000 07 Jan 2022 Common Shares 40,000 Direct F3, F5, F7
transaction BHVN Restricted Share Unit Award Options Exercise $0 -10,000 -25% $0.000000 30,000 07 Jan 2022 Common Shares 10,000 Direct F3, F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2 This balance includes 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2021.
F3 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
F4 The reporting person was granted 50,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date.
F5 Not applicable.
F6 The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date.
F7 The reporting person was granted 40,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date.

Remarks:

Exhibit List: Exhibit 24: Power of attorney